Millions of Americans Eligible for Type 2 Diabetes and Weight Loss Drug Semaglutide

New research has found that a staggering number of adults in the United States are eligible to take the type 2 diabetes and weight loss drug semaglutide, with nearly 137 million people qualifying for this medication. This number surpasses the amount of individuals eligible for statins, the most commonly prescribed cholesterol-lowering medications in the U.S.

Semaglutide, known under the brand names Ozempic, Wegovy, and Rybelsus, has seen a significant increase in prescriptions in recent years, with up to five million Americans receiving this drug in 2023. However, the high cost of semaglutide remains a barrier to access, as one month of treatment can cost around $900 to $1,350, with insurance coverage not always guaranteed.

Dr. Ivy Shi, a resident in Internal Medicine, emphasized the importance of equitable access to semaglutide and supporting individuals in staying on the therapy long-term. The rise in obesity rates and related conditions like type 2 diabetes has contributed to the growing number of people eligible for semaglutide.

Researchers also highlighted the potential expansion of semaglutide’s use beyond diabetes and weight management, including its effectiveness in chronic kidney disease and certain types of heart failure. This new research sheds light on the extensive population that can benefit from these drugs, prompting a call for greater access and affordability.

Individuals interested in semaglutide should consult with a healthcare provider to determine their eligibility for these medications. Ultimately, the decision to prescribe semaglutide will be made by a doctor based on individual health factors and conditions.